Hereditary Angioedema Market is anticipated to grow at a significant CAGR during the forecast period . The major factor that is expected to boost the market growth includes the increasing awareness regarding rare diseases, such as hereditary angioedema (HAE). The increased funding for rare genetic diseases and orphan drugs by governments and private companies is also increasing the pharmaceutical companies’ interest in developing drugs for hereditary angioedema, thus fuelling the market growth. For instance, in November 2020, Takeda Pharmaceutical entered an agreement for public funding of Takhzyro (Lanadelumab) in Canada to treat hereditary angioedema (HAE) patients. Hereditary angioedema is a disease characterized by recurrent episodes of severe swelling of the skin and mucous membranes. The swelling most commonly affects the arms, intestinal tract, legs, face, and airway and is usually not itchy.
The increasing R&D and funding for orphan drug development and rare genetic disorders are expected to further fuel the growth of the global hereditary angioedema market. For instance, the Indian Ministry of Health and Family Welfare developed a National Policy to treat rare diseases in India to progressively expand India’s capabilities to treat rare diseases. Hence, the increased funding for R&D for new drugs is propelling the growth of the market during the forecast period. Moreover, pipeline drugs is expected to offer an opportunity for the growth of the global hereditary angioedema market.
To Request a Sample of our Report on Hereditary Angioedema Market: https://www.omrglobal.com/request-sample/hereditary-angioedema-market
Recent Developments
- In December 2021, BioCryst Pharmaceuticals was granted $350 million to support fund the global launch of Orladeyo (Berotralstat), an oral treatment for prevention of hereditary angioedema (HAE) swelling attacks. It works by inhibiting kallikrein activity.
- In August 2020, the US Food and Drug Administration approved Takhzyro (Lanadelumab). It is the first monoclonal antibody that targets kallikrein and is indicated for treating patients aged 12 years and older with types I and II HAE.
Market Coverage
- The market number available for – 2022-2030
- Base year- 2022
- Forecast period- 2023-2030
Segment Covered-
- By Drug Class
- By Route of Administration
Regions covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape: Takeda Pharmaceutical Co. Ltd., Sanofi S.A., and Pharming Group, among others.
Hereditary Angioedema Market Report by Segment
By Drug Class
- C1 Esterase Inhibitor
- Selective Bradykinin B2 Receptor Antagonist
- Kallikrein Inhibitor
- Others
By Route of Administration
- Intravenous
- Subcutaneous Injection
- Oral
A full Report of Hereditary Angioedema Market is Available @ https://www.omrglobal.com/industry-reports/hereditary-angioedema-market
Hereditary Angioedema Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
